The collaboration aims to create a mouse model that integrates specific POLG mutations—which impair mitochondrial DNA replication—with proteins linked to Parkinson’s disease. Current models often fall short in replicating the clinical realities of these conditions, creating a significant barrier for drug discovery. By combining these genetic markers, researchers hope to establish a more reliable platform for testing therapeutic efficacy.

Dr. Carolyn Sue of Neuroscience Research Australia emphasized that this dual-disease approach is essential for understanding the aging population's neurological health. The effort follows recent clinical signals from Mighty’s research, including positive data from its MMPOWER-3 and NuPOWER studies regarding elamipretide. The company is also evaluating bevemipretide for Parkinson’s, supported by a 2023 grant from the Michael J. Fox Foundation. For families affected by rare POLG disorders, the project offers a pathway to decode the mechanics of mitochondrial dysfunction, which underpins not only rare genetic diseases but also broader neurodegenerative and systemic health challenges.